A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 16 May 2019
At a glance
- Drugs Imatinib (Primary) ; Ipilimumab (Primary)
- Indications Gastrointestinal stromal tumours; Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 19 Sep 2018 Planned End Date changed from 1 Feb 2020 to 28 Feb 2020.
- 19 Sep 2018 Planned primary completion date changed from 1 Feb 2020 to 28 Feb 2020.
- 31 Aug 2018 Biomarkers information updated